Dublin, Dec. 15, 2021 (GLOBE NEWSWIRE) -- The "CD47 Targeting Therapeutics Market Industry Trends and Global Forecasts, 2021-2035" report has been added to ResearchAndMarkets.com's offering.
According to the World Health Organization, at present, cancer is the second leading cause of death, worldwide. The National Cancer Institute (NCI) has estimated that, by 2030, over 22 million individuals are likely to be diagnosed with various types of cancer, in the US alone. As a result of the growing patient population affected by this disease, there is a rise in the demand for effective treatment modalities. The conventional approaches, such as chemotherapy, surgery and radiation therapy, employed for the treatment of oncological indication(s) are considered to be inadequate, specifically for late-stage cancers.
Therefore, in recent years, the focus of the research community has shifted towards the development of novel treatment modalities, such as T- cell immunotherapies, that exhibit high efficacy. However, certain limitations are associated with the aforementioned class of therapies as well; they have been demonstrated to have off-target and toxic side effects, including cytokine release syndrome and neurotoxicity. This has further led to significant research initiatives aimed at identifying target specific drug candidates.
Among such initiatives, CD47, owing to its increased expression on the surface of cancer cells, has emerged as a cancer immune checkpoint biomarker. Published literature further indicates that tumor growth and metastasis can be inhibited by blocking the interaction between CD47 and the signal-regulating protein alpha (SIRP?).
Currently, there are no approved therapies based on the inhibition of CD47/SIRP? pathway for advanced stage oncological indication(s), including myelodysplastic syndromes (MDS), non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Drug developers across the world claim to be evaluating several therapeutics, having dual specificities, in order to enhance the efficacy and expand the number of target modalities. In other words, candidates capable of targeting biomarkers, such as HER2, PD-L1, CD-38, CD-40 and CD-20, in addition to CD47, are being investigated across several studies.
Even though majority of the drug candidates are currently in preclinical/initial clinical stages, developers are optimistic regarding the therapeutic potential of this emerging class of drugs. Validation of the efficacy of anti-CD47 therapeutics as a promising treatment for oncological indications can be further asserted through the rapidly growing number of research publications, patents and clinical trials focused on this subject. The publishers believe that this niche, but upcoming market, is poised to witness healthy growth over the next decade, with pioneers in the field likely to benefit from the first-to-market advantage.
The report features an extensive study of the current landscape, offering an informed opinion on the likely adoption of CD47 targeting therapeutics in the healthcare industry, over the next 15 years. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain.
One of the key objectives of the report was to estimate the existing market size and future growth opportunity associated with CD47 targeting therapeutics developers, over the next 15 years. The report has provided an informed estimate of the market's evolution, during the period 2021-2035, based on several relevant parameters, such as adoption trends, and expected price variations for these products.
The report features the likely distribution of the current and forecasted opportunity within the CD47 targeting therapeutics market across
[A] target disease indication (acute myeloid leukemias, non-Hodgkin lymphoma, colorectal cancers, diffuse large b-cell lymphoma, myelodysplastic syndromes, non-small cell lung cancers, ovarian epithelial cancer, oral muscositis, small cell lung cancers),
[B] type of molecule (biologics and small molecules),
[C] key players and
[D] key geographical regions (US, France, Germany, Italy, Spain, UK, Australia, China, India and Israel).
In order to account for future uncertainties and to add robustness to the model, the report has provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.
Key Topics Covered:
- Market Overview
- Company Profiles
- Clinical Trial Analysis
- Publication Analysis
- Partnership and Collaborations
- Funding and Investments
- Key Opinion Leaders
- Emerging Trends on Social Media
- Company Competitive Analysis
- Big Pharma Players
- Start-up Health Indexing
- Market Sizing and Opportunity Analysis
- List of Companies and Organizations
Companies Mentioned
- 3D Medicines (3DMed)
- AbbVie
- Abpro
- Acerta Pharma
- Adage Capital Management
- Akeso
- Alector
- ALX Oncology
- Apmonia Therapeutics
- Arch Oncology
- Ascentage Pharma
- Aurigene Discovery Technologies
- Avego Healthcare Capital
- Avidity Partners
- Beijing Institute of Biotechnology
- BIOCAD
- Biotech Alliances International
- Bio-Thera Solutions
- BliNK Biomedical
- bluebird bio
- Boehringer Ingelheim
- Boxer Capital
- Bristol-Myers-Squibb
- BVF Partners
- Cancer Focus Fund
- Chinese Academy of Sciences
- Chinook Therapeutics
- Clarus Ventures
- Conjupro Biotherapeutics
- Cormorant Asset Management
- Cowen Healthcare Investments
- DAFNA Capital Management
- EcoR1 Capital
- Eli Lilly
- Elpiscience
- Emerson Collective
- EMulate Therapeutics
- EpicentRx
- Eventide Asset Management
- Flerie Invest
- FMB Research and Broadfin
- Foresite Capital
- Forty Seven
- Genentech
- Genmab
- Gilead Sciences
- GlaxoSmithKline
- Hadasit Bio Holdings
- Hanmi Pharmaceuticals
- Hatteras Venture Partners
- HBM Healthcare Investments
- Ichnos Sciences
- I-Mab Biopharma
- ImmuneOncia Therapeutics
- ImmuneOnco Biopharmaceuticals
- Innovent Biologics
- ISU ABXIS
- Janssen
- Janus Henderson Investors
- K2 HealthVentures
- KAHR Medical
- Li Cheng Enterprise
- Light Chain Bioscience
- Lightspeed Venture Partners
- Lightstone Ventures
- Lilly Asia Ventures (LAV)
- Logos Capital
- Lonza
- LYFE Capital
- Lynkcell
- MacroGenics
- Merck
- Mirae Asset Venture Investment
- Morphiex Biotherapeutics
- Mountain Pacific Venture
- Navigen Pharmaceuticals
- New Enterprise Associates
- Novimmune
- Novo Nordisk
- Ono Pharmaceutical
- Oriella
- OSE Immunotherapeutics
- Partner Fund Management
- Pavilion Capital
- Peregrine Ventures
- Pfizer
- PharmAbcine
- Piper Sandler
- Point72 Asset Management
- QLSF Biotherapeutics
- Redmile Group
- RiverVest Venture Partners
- Roche
- Roche Venture Fund
- Saiyuan
- Samsung BioLogics
- Sanquin
- SATT Nord
- SciClone Pharmaceuticals
- Shattuck Labs
- Shavit Capital
- Sorrento Therapeutics
- Sutter Hill Ventures
- SWISS BIOPHARMA MED
- Synthon Biopharmaceuticals
- Tallac Therapeutics
- TG Therapeutics
- Thomas Jefferson University
- Trillium Therapeutics
- venBio
- Venrock Healthcare Capital Partners
- Vivo Capital
- Vivoryon Therapeutics
- Waterstone Hanxbio
- Xinxiang Medical University
- Zai Lab
- Zymeworks
For more information about this report visit https://www.researchandmarkets.com/r/ix1pw5
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
